Pharm Exec4h
The Bottlenecks Blocking Cell and Gene Therapy
Jason Foster, CEO of Ori Biotech, discusses the difficulties preventing more widespread adoption of these advanced therapies.
Pharm Exec18h
FDA Approves Incyte and Syndax’s Niktimvo for Chronic Graft-Versus-Host Disease in 9 and 22 mg Vial Sizes
Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic ...
Pharm Exec21h
FDA Approves Eli Lilly’s Omvoh for Crohn Disease
Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...
Pharm Exec20h
AD04-13 Study Highlights Consistent Bioavailability and Safety for Alcohol Use Disorder Treatment
Cary Claiborne, CEO, Adial Pharmaceuticals, discusses promising results of the AD04-13 study in patients with Alcohol Use Disorder ...